Sun Pharma’s Q1FY23 Quarter Results
Sun Pharma reported 9% YoY revenue growth
- 29 Jul 2022
- Sun Pharma reported 13% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended June (Q1FY23). On a year-on-year (YoY) basis, it witnessed a growth of 9%.
- Its expenses for the quarter were up by 10% QoQ and 14% YoY.
- The net profit increased by 43% on a YoY basis..
- The earnings per share (EPS) of Sun Pharma stood at 8.6 during Q1FY23..
Sun Pharma’s Financial Statements for Q1FY23:
Total Income | 9,871 | 9,560 | 10,764 | 13% | 9% |
Total Expenses | 7,436 | 7,700 | 8,479 | 10% | 14% |
Profit before tax | 1,804 | -2,076 | 2,285 | - | 27% |
Tax | 396 | 147 | 189 | 29% | -52% |
Profit after tax | 1,444 | -2,277 | 2,061 | - | 43% |
Earnings per share | 6.0 | - | 8.6 |
Data Source: BSE, Company announcements
Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Neo.
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Open Demat Account
